Core Viewpoint - The acquisition of 90% stake in Siwei Medical for 250 million yuan marks a significant step for the company, which is expected to enhance its capabilities in AI medical applications and drug development [1][2]. Group 1: Financial Performance - In 2024, the company achieved revenue of 266 million yuan, representing a year-on-year increase of 52.8%, driven by an 87.8% growth in intelligent robot solutions and an 18.2% increase in drug discovery solutions [1]. - The adjusted net loss for 2024 was 457 million yuan, narrowing by 12.5% year-on-year, indicating potential for profitability as revenue scales up [1]. - As of December 31, 2024, the company had cash reserves of 3.123 billion yuan, which, when combined with net proceeds from two placements in Q1 2025 amounting to 2.968 billion yuan, is expected to support operations for the next decade [1]. Group 2: Business Development and Partnerships - The drug discovery solutions generated revenue of 104 million yuan in 2024, reflecting an 18.2% increase, attributed to a growing customer base and revenue-generating projects [2]. - The company has established commercial licensing agreements with major pharmaceutical companies such as Johnson & Johnson and AbbVie, leveraging its leading protein interaction prediction algorithm, XtalFold [2]. - Strategic collaborations with biotech leaders in East Asia have been formed to efficiently design and discover lead compounds for challenging targets [2]. Group 3: Market Position and Future Outlook - The global new materials market is projected to exceed 10 trillion USD, presenting significant growth opportunities for the company [2]. - The company has entered into a five-year strategic R&D cooperation agreement with GCL Group to develop AI perovskite materials and has delivered electrolyte materials to a research team at Peking University [2]. - The company is also collaborating with leading carbon material firms to advance AI-driven high-end carbon material development and has provided high-throughput synthesis and catalyst analysis solutions to China Petroleum & Chemical Corporation [2].